Introduction
The goal of palliative care is to improve the disease experience for all patients, irrespective of the outcome. 1 In addition to symptom management, the scope of palliative care includes emotional, spiritual, and social needs of patients, their families and friends, and their caregivers. Many palliative care specialists believe that healing is always achievable even when cure is out of reach, because healing involves patients coming to terms with their disease and its symptoms and outcome. 2 Palliative care in older patients with cancer is important because integrating palliative care into stan-By the year 2020, more than 50% of patients diagnosed with cancer will be aged 70 years and older. 4 In addition, older individuals may present different issues unrelated to cancer than their younger counterparts that make palliative care both urgent and challenging. 4 
Assessing Physiological Age
Aging may be defined as a progressive loss of functional reserve in multiple organ systems that eventually leads to disability and death. 5 Thus, social support becomes important to the welfare and survival of persons who are elderly when they are unable to accomplish instrumental or basic activities of daily living.
Aging is universal but highly individualized, and physiological age is poorly reflected in chronological age. 5 Thus, assessing physiological age is paramount to any medical decisions related to older individuals. In the case of cancer management, the questions facing the health care professional may include:
• Will the patient die of cancer or with cancer?
• Is the patient likely to experience consequences of cancer during his or her lifetime? • Will the patient tolerate the treatment proposed?
• What might be the long-term consequences of cancer and its treatment in this patient?
The assessment of physiological age is founded on the comprehensive geriatric assessment (CGA), which encompasses medical, emotional, and social domains, because aging is multidimensional and the assessment of several domains is necessary to estimate life expectancy and stress tolerance (Table 1) .
Several models integrating the CGA with clinical and laboratory parameters allow estimates of tolerances of surgery, cytotoxic chemotherapy, and life expectancy independent of cancer. [6] [7] [8] [9] This information may be used in negotiating and determining the most appropriate treatment for each patient.
Function is assessed in the CGA as a patient's ability to perform instrumental and basic activities of daily living, because they have prognostic value independent of performance status. No consensus exists concerning the best way to assess polymorbidity and polypharmacy. Several comorbidity scales that account for the number and the severity of comorbid conditions are in use. 10 The definition of polypharmacy may include the number of daily drugs, medication redundancy, drugs contraindicated in older individuals, risk of at least a type 1 drug interaction, and the absence of drugs that may be appropriate. 11 Depression, including subclinical depression, has been associated with increased risk of mortality if it is left untreated; depression can be assessed with a number of screening tests. 12 Many older individuals may be malnourished or at risk of malnutrition; cancer alone is a cause of malnutrition. 13, 14 Both forms of malnutrition can be estimated with the Mini Nutritional Assessment, a commonly used tool. Malnutrition is associated with increased mortality rates, surgery risks, and chemotherapy-related complications. 15 A number of simple tests may be utilized to screen a patient for memory disorders associated with decreased rates of survival. Of these, the Minimental status, Montreal Cognitive Assessment, and Saint Louis University Mental Status Exam are commonly used tools. 16 Assessment of social support status includes available resources, the need for a caregiver, and the caregiver's availability and effectiveness. 17 Geriatric syndromes involve several conditions that become more common with age, although they are not unique of aging, and purport decreased life expectancy and increased risk of functional dependence. 18 In addition to estimating cancer-independent life expectancy and risk of treatment-related toxicity, the CGA helps to determine the existence of unsuspected conditions that could interfere with antineoplastic treatment, including various diseases, depression, initial memory disorders, inadequate resources, and inadequate caregiver support. 19 Many other instruments have been proposed to assess life expectancy and risk of disability but none has been validated in patients with cancer; however, the "inflammatory index" has been validated in 2 large cohort studies of aging populations. 20 Age-related inflammation may be considered chronic and progressive, and the concentration of inflammatory markers, such as cytokines and fibrinolytic products, has been associated with decreased life expectancy and increased risk of disability. The inflammatory index, ie, the sum of the logarithm of interleukin 6 and tumor necrosis factor-α receptor 1 in the circulation, is the most reliable predictor of long-term mortality. 20 It is unclear how cancer-related inflammation might affect the inflammatory index.
Frailty is a term often used in the geriatric and geriatric oncology literature. 21 Frailty can be interpreted in 2 ways. In one case, it is considered a threshold, a critical loss of functional reserve beyond which any stress, even minimal, may have catastrophic consequences. In the other case, it is considered a continuum, a measurement of the degree of aging.
Pharmacology of Aging
Aging is associated with changes of pharmacokinetics and pharmacodynamics that may affect oncology treatment and the symptoms of cancer (Table 2) . 22 Reducing the volume of distribution of hydrosoluble agents may be related to reduced total body water, reduced concentration of plasma proteins, and reduced mass of red blood cells, leading to increased area under the curve and toxicity measures of these hydrosoluble medications. It may be mitigated with the correction of anemia.
CYP450 hepatic reactions are the most common site of drug interactions. Patients who are elderly are at increased risk for these interactions due to decreased activity of these reactions and polypharmacy.
Reduced glomerular filtration rate appears to decrease the excretion of medicaments as well as their active metabolites. For example, although anthracyclines are excreted with bile, some of these anthracyclines give rise to active metabolites (daunorubicinol, idarubicinol) excreted from the kidneys. When the glomerular filtration rate is reduced, compound toxicity, including myelotoxicity, cardiotoxicity, and mucositis, may be increased. Morphine and its congeners are partly metabolized to 6-glucuronides that are active and renally excreted. The increased area under the curve of these metabolites may partly explain the increased effectiveness and toxicity of opioids in older individuals.
Aging is associated with increased risk for myelotoxicity, mucositis, peripheral neurotoxicity, and cardiotoxicity from cytotoxic agents. Decreased brain volume appears to increase the risk of medication-related delirium, whereas changes in μ:δ opioid receptors may partly explain the increased risk of opioid-related complications. 23 These complications can include delirium, constipation, nausea, and vomiting.
Setting Treatment Goals
Setting treatment goals is the first step of personalized care. The goals of treatment include cure, symptom management, prolonging survival, and preserving quality of life, as well as prolonging active life expectancy -that is, maintaining functional independence and preventing functional decline in older individuals. 24 Loss of independence is universally recognized as the worst threat to quality of life in older patients. 25 Treatment goals may be at odds with each other. For example, adjuvant treatment improves the likelihood of cure for cancers of the breast, lung, large bowel, and bladder, but it may be associated with intolerable complications. Aromatase inhibitors that represent the hormonal treatment of choice for hormone-sensitive breast cancer can cause severe joint pain and, thus, lead to functional decline, as well as vaginal dryness and dyspareunia. Approximately 15% of older women decide to forgo a higher likelihood of cancer control because of these complications. 26 Peripheral neuropathy is a disabling complication of chemotherapy for older individuals and may be caused by drugs commonly used for adjuvant treatment, such as platinum derivatives and taxanes. 22 In most cases, the decisions of forgo chemotherapy is made following exposure to one of these agents, and, in some cases, the decision may be made due to compelling reasons prior to initiating treatment (eg, patients involved in activities that require manual dexterity).
Realistic treatment goals should be established prior to initiating treatment and revisited during the course of the treatment. Initial goals should be based on patient desires, cancer stage, aggressiveness and responsiveness to treatment, life expectancy, risk of complications, and available resources (Fig) . However, it is important to remember that the values and desires of the patient are paramount in situations in which prolonging survival might be achieved at significant personal cost.
The role of the caregiver when he or she is unable or unwilling to provide necessary care is an unresolved and vexing problem. 27 Caregivers should provide timely access to health care professionals and to emergency care, provide assistance at home (eg, symptom management, aid in instrumental activities of daily living that the patient is no longer able to perform), and emotionally support the patient. In some instances, the caregiver may act as the family spokesperson within the health care system and may help manage conflicts within the family relating to the patient. In general, the primary caregiver of an older patient with cancer is an elderly spouse with health conditions of his or her own or an adult child who has professional and family responsibilities of his or her own ("Aeneas syndrome"). 28 Thus, assessment of the caregiver should be part of the initial evaluation of an older patient undergoing any form of antineoplastic treatment; the health care professional can be aided by a social worker to evaluate the availability, the capability, and the willingness of the caregiver. If the results of such an assessment prove inadequate, then alternative solutions should be sought (eg, involvement of other family members or other caregivers).
The caregiver represents a valuable ally for the health care team and is likely to make a difference in the patient's experience; however, caregivers may be susceptible to severe emotional and physical stress that may lead to disease, including depression, disability, and increased mortality. 29 This stress may impact the family of the caregiver as well as compromise the work quality and productivity of the caregiver. By contrast, caregiving can be a rewarding emotional and spiritual experience that inspires self-worth. 30 Thus, the health care professional must train and support the caregiver by providing a realistic outline of the likely course of the disease and of the difficulties that may emerge, as well as potential solutions, by allowing caregivers to express concerns and show sympathy for them, and by directing caregivers to available resources (eg, support groups). In each encounter with the health care team, the patient and caregiver should be recognized as a dyad held together by the patient's disease and treatment.
Management

Treatment-Related Complications
Complications of radiation therapy and systemic cancer treatment, including hormonal therapy, cytotoxic 
Treatment
Effectiveness
Toxicity Cost chemotherapy, and targeted therapy, are shown in Table 3 .
Osteoporosis is a complication of aromatase inhibitors that may be used for the treatment of breast cancer, and androgen deprivation treatment (ADT), which may be used for prostate cancer; the risk for osteoporosis may offset the potential benefits. 31 For example, in an older woman prone to falls, aromatase inhibitors may prove more hazardous than the recurrence of breast cancer. Select patients with prostate cancer may undergo ADT for a small increase of prostatespecific antigen in the serum after definitive treatment of the cancer; however, no evidence suggests that this practice is beneficial in the absence of disease (based on imaging results), whereas evidence suggests that the risk of bone fractures increases by 50% after 1 year of ADT. 31 Health care professionals must check bone density at the beginning of a patient's treatment; if the value is normal, then it should be maintained with adequate intake of calcium and vitamin D. In the presence of osteopenia and osteoporosis, then more aggressive treatment with bisphosphonates or denosumab may be indicated. Some studies have shown that an intensive schedule of intravenous zoledronic acid may prevent osteoporosis and cancer recurrence in postmenopausal women receiving adjuvant treatment with an aromatase inhibitor. 32, 33 Thus, the potential benefit of zoledronic acid should be weighed against its inconvenience, cost, and risk for osteonecrosis of the jaw.
Myelodepression from cytotoxic chemotherapy is more prolonged and more severe in older individuals, and it may be further aggravated by combination chemotherapy/radiotherapy to the chest. 22 The risk and duration of neutropenia and of neutropenic infections increases with age, and patients aged 65 years or older are at increased risk for such complications. In addition to severe and sometimes lethal infections, another risk of neutropenia includes treatment delay, and both may cause decreased therapeutic benefits. When myelodepression is managed with dose reduction and delayed treatment administration, neutropenia can lead to a decrease in the treatment dose and intensity, which may result in reduced effectiveness. Myelopoietic growth factors (filgrastim and pegfilgrastim) are effective in older individuals. 22 Guidelines recommend that patients treated with a chemotherapy dose in an intensity comparable with cyclophosphamide/doxorubicin/vincristine/prednisone receive prophylactic growth factors to prevent neutropenic infections instead of treatment delays or dose reductions. 34, 35 Several techniques reduce the damage of radiation to normal tissues. The most serious complications of radiation damage are seen from combination chemotherapy/radiotherapy in the management of cancer of the upper airways, the esophagus, and the lungs. 36 Severe mucositis may lead to dysphagia, malnutrition, and dehydration. Given the limited nutritional and hydric reserve of the elderly, these complications may be more severe and lethal for older individuals. The prophylactic insertion of a gastric or jejunal tube helps provide the patient with nutrition and fluids throughout treatment. In addition, the prophylactic use of hypersaturated calcium solution may assuage the pain of mucositis in the upper digestive tract. Laser and light therapy as well as cryotherapy represent promising treatment options for oral mucositis. When mucosal infections are present, they must be treated, otherwise management consists of temporarily discontinuing oncology treatment and managing pain with opioids. Even in the absence of radiotherapy, mucositis may result from cytotoxic chemotherapy, particularly fluorouracil, methotrexate, and doxorubicin. The management is the same as that recommended for combined chemotherapy/radiotherapy. A keratinocyte-stimulating factor may reduce the risk of mucositis, but it is expensive and cumbersome to administer. Its prophylactic use is not recommended. Diarrhea is a common complication of the same drugs that cause mucositis, tyrosine kinase inhibitors, and radiotherapy to the pelvis, although the use of image-modulated radiation therapy or protons can reduce the risk of diarrhea. In addition to the use of antidiarrheal medication, maintaining proper hydration is paramount. 37 In some resistant cases, octreotide may be used. Lactobacillus may be useful in chemotherapy-induced diarrhea and hyperbaric oxygen in radiation proctitis. 36 Diarrhea is also a common complication of immune check-point inhibitors, such as ipilimumab, nivolumab, and pembroluzimab. 38 In such a case, diarrhea is autoimmune related and may respond to steroids.
Many different medications can cause peripheral neuropathy, which is common in patients treated with platinum derivatives (eg, oxaliplatin) and taxanes. 22 Peripheral neuropathy may cause symptoms such as loss of sensation, paresthesias, shooting pain, burning pain, weakness, and paresis. One prophylaxis for neuropathy is effective, and that is the timely discontinuance of the offending agents. In some cases, neuropathic pain may respond to high-dose gabapentin or pregabalin, but these drugs may cause somnolence and confusion in older individuals. 39 Numbness may be associated with difficulty performing basic and instrumental activities of daily living as well as unstable gait and falls.
Cardiomyopathy is a complication of anthracyclines, anthracenediones, and cyclophosphamide in high doses. Anthracycline-related cardiomyopathy may be due to progressive damage of the myocardium by free radicals, and it may be irreversible. 40 It is rare prior to a total dose of doxorubicin of 300 mg/m 2 (and equivalent doses of other anthracyclines). 40 Several approaches may prevent this complication and include concomitant administration of dexrazoxane to prevent the formation of free radicals, administration of doxorubicin as a continuous intravenous infusion, or taken as a low daily dose, and use of liposomal pegylated preparations. Dexrazoxane may enhance other treatment complications, including myelosuppression and mucositis. According to the results from 1 study, dexrazoxane may diminish the antineoplastic effect of doxorubicin. 40 In general, dexrazoxane is recommended only after at least 2 doses of anthracycline. Administering doxorubicin via continuous infusion may be cumbersome outside of major academic centers, and its effectiveness has been confirmed only in sarcomas and in myeloma. 40 Data are insufficient for recommending low daily doses of anthracyclines. Pegylated liposomal doxorubicin may be used in lieu of doxorubicin in patients at high risk of cardiomyopathy, but whether its effectiveness is comparable with doxorubicin is unknown.
A different form of cardiac toxicity that is, in most cases, reversible can be caused by the monoclonal antibody trastuzumab, which causes a condition of frozen myocardium; discontinuing the drug reverses the effect. 41 Risk of cardiac toxicity with trastuzumab also increases with age, and management consists of suspending the administration of trastuzumab, although the drug may be safely restarted when myocardial function has been restored.
Cancer-Related Complications
The most common symptom of cancer in older individuals is fatigue. 42 Other important manifestations include pain and malnutrition.
Fatigue: Fatigue is a condition of exhaustion that does not improve with rest and that interferes with individual functions. The prevalence of fatigue, even in the absence of cancer, increases with age; in older individuals, fatigue is associated with increased risk of functional deficiency and death. 43 The mechanisms of fatigue are multiple and not fully understood; they may include increased concentration of inflammatory cytokines in the circulation, tissue hypoxia from anemia, hypogonadism-associated ADT, and sarcopenia, a catabolic condition associated with aging that may be related to a combination of inflammation, malnutrition, and endocrine senescence. 44 Radiotherapy and cytotoxic chemotherapy may cause fatigue at least in part through treatment-related anemia.
Management of fatigue is controversial and unsatisfactory. 42 There is consensus that exercise prevents fatigue, but only if the patient is able to follow an exercise program during cancer treatment. 45 Correction of anemia with erythropoiesis-stimulating agents may improve energy level. Although concern exists that erythropoiesis-stimulating agents may stimulate tumor growth, these agents appear safe when the hemoglobin level is not above 12 g/dL and they are used only in patients receiving cytotoxic chemotherapy. 44 Blood transfusions may also relieve fatigue but only for a limited time.
Pain: The perception of somatic and visceral pain may decrease with age. 46 For example, it is not uncommon in older individuals to experience silent myocardial infarction or silent intestinal perforation. Older individuals may have a higher tolerance of pain, because they may consider pain an expected consequence of aging. However, bone pain, in particular, may represent a serious limitation to patient activity and independence.
As in any other individual, the assessment of pain of older individuals includes:
• Type of pain (eg, dull, aching, burning, spasmodic, shooting) • Localization • Conditions that elicit pain (eg, particular movements, positions) • Grade of pain on a pain scale
It is important to note that pain may have some atypical manifestations in older individuals; of these, delirium is one of the most common manifestations.
Another age-related challenge is assessing pain in individuals with dementia or in those unable to communicate. 46 However, select behavioral manifestations, including grimaces, grunting, screaming, or withdrawal, may suggest the need to manage pain.
The management of pain depends on many factors, including the type, location, and intensity of the pain. The most common form of pain is bone pain from metastases. When the pain is localized to a single area, local radiotherapy may suffice. If bone metastases are numerous, then relief of pain in one area may result in the emergence of pain in different areas. Systemic cancer treatment, if effective, represents the most definitive and lasting treatment of pain. Timely use of intravenous bisphosphonates or denosumab may mitigate the symptoms and delay the development of pain. Select radioisotopes are available for the management of bone pain; of these, radium 223 has been shown to relieve pain, with minimal marrow damage, in patients with castrate-resistant prostate cancer. 47 Pharmacological management is the mainstay of acute pain control. 48, 49 Tapering doses of steroids may provide temporary relief of bone pain. Nonsteroidal anti-inflammatory drugs have limited use in older patients due their risks of gastritis and renal insufficiency. Opioids represent the most beneficial class of drugs, but their dose should be slowly titrated because the risk of complications may increase with age. 48 Intrathecal administration of opioids may prevent most other types of complications, but this route of administration is cumbersome, expensive, and associated with the risk of spinal infections. 48 Administration of opioids should be complemented by a prophylactic bowel regimen to prevent constipation. Methylnaltrexone relieves opioid-related constipation without interfering with analgesic activity.
49,50
Malnutrition: Malnutrition is common, especially in most advanced cancer stages. 51 In patients with cancer of the esophagus and upper digestive tract, malnutrition is often present at diagnosis. Malnutrition is due to a combination of factors, including the consumption of tissues by the cancer, decreased food intake, and absorption. 52 Anorexia may be prominent during the last phases of cancer and appears to be mediated by increased concentration of 5HT3 and tryptophan in the brain stem. 31 Nutritional support is an essential treatment component for patients with a treatable neoplasm, because malnutrition increases the risk of complications of surgery, radiotherapy, and cytotoxic chemotherapy. 52 Enteral nutrition is more effective than parenteral nutrition and is preferred in the presence of a functional gastroenteric tract. Prophylactic insertion of gastric or jejunal tubes in the presence of an impending obstruction of the esophagus and upper digestive tract and the aggressive prevention and management of mucositis, nausea, and vomiting are effective and recommended. The management of anorexia is not well established. The effectiveness of cannabinoids is controversial; use of medroxyprogesterone at a high dose appears to stimulate the appetite, but it may not increase the lean body weight of patients. Anamorelin, which is a synthetic analog of the gastric hormone ghrelin, appears promising in early clinical trials. 53 Nutritional support of any type fails to improve the lean body weight of patients whose neoplasm is advanced and untreatable and does not affect the survival of such patients. Hyperalimentation may have a detrimental effect on survival. For these patients, nutritional support is indicated only if it is necessary to maintain quality of life.
Survivor Care
The survival rates of most cancers have improved for patients of all ages; however, a consensual definition of "survivor" is needed. 54 Few data relate to elderly patients who have survived cancer. It is well known that age is a risk factor for developing acute leukemia after cytotoxic chemotherapy, and older cancer survivors are at increased risk of developing a second cancer that may be related or unrelated to the original one. At present, evidence is insufficient to suggest that elderly patients who are survivors of cancer may benefit from additional cancer screening.
The main concerns related to elderly cancer survivors include functional dependence and memory disorders. 45 Functional dependence may result from a combination of factors, including peripheral neuropathy, sarcopenia, and fatigue. Fatigue appears to play a major role because it is associated with increased risks of functional dependence and mortality among older patients. The most effective treatment of fatigue appears to be prevention through regular exercise, nutritional preservation, correction of anemia, and depression management, beginning at the time oncology treatment is initiated.
Whether cancer and its treatment are associated with full-blown dementia is controversial; however, cognitive function has been shown to decline as a result of treatment, and this decline may cause distress in patients and their loved ones. 45 Distress may be prevented by anticipating the possibility of cognitive decline, but reassuring the patient might include performing a neuropsychological evaluation. The fear of cognitive decline appears to be a major cause of distress, and, thus, normal findings may reassure the patient that decline has not occurred.
Conclusions
The goal of palliative care is to improve the patient experience; thus, palliative care is most effective when administered together with antineoplastic treatment. After the evaluation of the disease, life expectancy, functional reserve, and treatment goals of the patient should be reviewed and assessed -a process that should be continually reviewed throughout the course of treatment. When feasible, common treatment complications, such as neutropenia and neutropenic infections, should be prevented. Management of fatigue, pain, and malnutrition are paramount to the success of treatment. More information is needed on the elderly cancer survivors, particularly as to whether elderly patients should undergo additional cancer screening and determining the most effective management options for fatigue and cognitive decline in elderly patients.
